tecentriq
Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer
July 2, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer
March 20, 2019Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …
Roche’s first-line Tecentriq combo scores accelerated FDA review
December 5, 2018Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide …
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
November 19, 2018Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …
Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer
October 22, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq
Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …
Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer
September 26, 2018Research and Development Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy …
Roche’s Tecentriq combo extends life in untreated lung cancer
June 25, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer, pharma, tecentriq
Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
May 29, 2018Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
Roche gets NICE approval for advanced bladder cancer
May 17, 2018Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …
Roche’s Tecentriq/Cotellic combo therapy fails to impress in colorectal cancer
May 11, 2018Medical Communications, Research and Development Cancer, Cotellic, Roche, pharma, tecentriq
Roche has been rocked by a Phase 3 weak showing from its combination Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people …
Roche’s immunotherapy lucky streak ends with deaths in trial
April 13, 2018Medical Communications, Research and Development Exelixis, Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Roche’s Tecentriq had begun to show signs of reviving its hopes in the competitive PD-1/L1 market, succeeding in two Phase …
Tecentriq third time lucky after NICE nod in lung cancer
April 9, 2018Sales and Marketing NICE, Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq
After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
